These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26804741)

  • 21. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections.
    Maurice NM; Bedi B; Sadikot RT
    Am J Respir Cell Mol Biol; 2018 Apr; 58(4):428-439. PubMed ID: 29372812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology.
    Costabile G; d'Angelo I; Rampioni G; Bondì R; Pompili B; Ascenzioni F; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Miro A; Quaglia F; Imperi F; Leoni L; Ungaro F
    Mol Pharm; 2015 Aug; 12(8):2604-17. PubMed ID: 25974285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a novel series of non-natural triaryl agonists and antagonists of the Pseudomonas aeruginosa LasR quorum sensing receptor.
    Capilato JN; Philippi SV; Reardon T; McConnell A; Oliver DC; Warren A; Adams JS; Wu C; Perez LJ
    Bioorg Med Chem; 2017 Jan; 25(1):153-165. PubMed ID: 27825554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pseudomonas aeruginosa hypoxic or anaerobic biofilm infections within cystic fibrosis airways.
    Hassett DJ; Sutton MD; Schurr MJ; Herr AB; Caldwell CC; Matu JO
    Trends Microbiol; 2009 Mar; 17(3):130-8. PubMed ID: 19231190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.
    Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB
    BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.
    Liebens V; Defraine V; Knapen W; Swings T; Beullens S; Corbau R; Marchand A; Chaltin P; Fauvart M; Michiels J
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapies for pneumonia.
    Ricard JD
    Curr Opin Pulm Med; 2012 May; 18(3):181-6. PubMed ID: 22388584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of bacterial biofilms in chronic infections.
    Bjarnsholt T
    APMIS Suppl; 2013 May; (136):1-51. PubMed ID: 23635385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plant-derived Compounds as Potential Source of Novel Anti-Biofilm Agents Against Pseudomonas aeruginosa.
    Chung PY
    Curr Drug Targets; 2017; 18(4):414-420. PubMed ID: 27758704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity of mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa.
    Tetz G; Vikina D; Tetz V
    Ann Clin Microbiol Antimicrob; 2016 Mar; 15():19. PubMed ID: 27001074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides.
    Dosler S; Karaaslan E
    Peptides; 2014 Dec; 62():32-7. PubMed ID: 25285879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms.
    Chua SL; Yam JK; Hao P; Adav SS; Salido MM; Liu Y; Givskov M; Sze SK; Tolker-Nielsen T; Yang L
    Nat Commun; 2016 Feb; 7():10750. PubMed ID: 26892159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Hurley MN; Cámara M; Smyth AR
    Eur Respir J; 2012 Oct; 40(4):1014-23. PubMed ID: 22743672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New perspectives in the management of Pseudomonas aeruginosa infections.
    Savoia D
    Future Microbiol; 2014; 9(7):917-28. PubMed ID: 25156380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to manage
    Bassetti M; Vena A; Croxatto A; Righi E; Guery B
    Drugs Context; 2018; 7():212527. PubMed ID: 29872449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The implication of Pseudomonas aeruginosa biofilms in infections.
    Rybtke MT; Jensen PØ; Høiby N; Givskov M; Tolker-Nielsen T; Bjarnsholt T
    Inflamm Allergy Drug Targets; 2011 Apr; 10(2):141-57. PubMed ID: 21314623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo.
    Uusitalo P; Hägglund U; Rhöös E; Scherman Norberg H; Elofsson M; Sundin C
    J Antibiot (Tokyo); 2017 Aug; 70(9):937-943. PubMed ID: 28588224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic resistance in Pseudomonas aeruginosa biofilms: towards the development of novel anti-biofilm therapies.
    Taylor PK; Yeung AT; Hancock RE
    J Biotechnol; 2014 Dec; 191():121-30. PubMed ID: 25240440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.